Q-State Biosciences, now known as Quiver, employs a sophisticated platform to advance drug development for neurological disorders. Their approach integrates cutting-edge scalable biology, advanced technology, and engineering to identify novel therapeutic targets and candidate molecules. Central to their methodology are proprietary cellular models that encompass the entire human genome, allowing for the production of billions of cryopreservable neurons derived from over 500 patient and CRISPR-edited cell lines. This extensive foundation supports the discovery process by capturing the complexities of human biology. Additionally, Quiver utilizes a suite of proprietary technologies to measure various cellular functions at an unprecedented resolution, generating vast datasets that inform their understanding of disease mechanisms and therapeutic responses.

Quiver's innovative technologies include the Swarm™ optogenetic measurement system, which enables high-throughput, multicolor recordings of cellular activity, and the Genomic Positioning System (GPS), which combines human neuronal electrophysiology data with AI and machine learning to derive insights for drug discovery. These systems facilitate the identification of disease-relevant cellular features and the optimization of therapeutic candidates. By leveraging these advanced tools, Quiver aims to bridge the gap between genetic expression changes and clinical outcomes, ultimately driving the development of precision therapies for serious central nervous system disorders.

United States

Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.

Q-State Biosciences

Company Details